WEBULL
WebtradeDownload

Yatsen Holding (YSG) Stock Grapples With Widening Losses And Thinner Margins

Simply Wall St · 2d ago

Yatsen Holding shareholders walked into this earnings print already bruised, with the stock down about 20% over the past month, and the selling pressure did not ease. The share price fell a further 6.3% to US$2.37 as investors reacted to a headline that mixed solid skincare momentum with a sharp profit squeeze.

The market appears to be focused on that squeeze. Q2 revenue reached RMB 1.14b, while the company reported a net loss of RMB 90.8m and a wider operating loss, as heavier marketing and inventory clean up weighed on results. Attention is on the losses, while the full skincare narrative remains in the background.

Love Yatsen Holding's skincare traction but concerned about the profit squeeze and heavier marketing spend? Check out list of solid balance sheet and fundamentals stocks (53 results).

Q2 2026 Earnings Summary

  • Revenue (Q2 2026 vs. Q2 2025): RMB 1,142.18m vs. RMB 1,086.73m (up 5.1%)
  • Net Income or Loss (Q2 2026 vs. Q2 2025): net loss of RMB 90.83m vs. net loss of RMB 17.67m (loss widened)
  • Basic EPS (Q2 2026 vs. Q2 2025): loss per share of RMB 0.97 vs. loss per share of RMB 0.19 (loss per share increased)
  • Gross Margin (Q2 2026 vs. Q2 2025): 73.9% vs. 78.3% (margin compressed)

Prefer clear visuals over scrolling through another wall of earnings tables and commentary? See Yatsen Holding's full financial picture, including how its recent losses fit into the broader income statement trend, in the interactive company report for Yatsen Holding.

NYSE:YSG Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026
NYSE:YSG Trailing 12-Month Revenue & Expenses Breakdown as at Sep 2026

Evaluating Yatsen Holding’s Skincare Led Bull Case

Bulls argue that Yatsen Holding can use R&D led skincare and omnichannel execution to drive higher quality growth and structurally better margins. Q2 hits some key proof points. Skincare revenue grew 40.4% year on year and now accounts for 71.5% of the business. That mix shift is exactly what believers in a premium, higher margin portfolio wanted to see.

The company also kept R&D steady at 3.3% of revenue and secured national recognition for its Global Innovation R&D Center, while DR.WU produced three SCI indexed papers. Those are tangible steps toward the science backed brand story bulls expect to support pricing power over time. On the efficiency side, fulfillment costs improved to 4.9% of revenue, which fits the argument that a more scaled, omnichannel model can become leaner as it matures, even as Yatsen leans into heavier brand marketing.

Reveal whether Wall Street thinks Yatsen Holding’s skincare shift can actually repair this profit profile. Compare the story from management to the consensus price target analysis for Yatsen Holding.

Yatsen Holding Bears See Profit Path Slipping

The bearish view on Yatsen Holding is that heavy R&D, high marketing and complex SG&A keep the business stuck in loss making mode, even as management talks up premium skincare and omni channel gains. Q2 gives that concern real footing. Revenue grew 5.1%, yet the operating loss widened to RMB 131.9m and net loss deepened to RMB 90.8m. Non GAAP swung from profit a year ago to a loss of RMB 99.4m. Marketing climbed to 70.7% of revenue, directly in line with concerns that competitive pressure forces higher spend and compresses margins.

Guidance for Q3 revenue roughly flat to down 10% reinforces the idea that growth is not yet absorbing the cost base. Cash of about RMB 1.06b and recent convertible financing address liquidity, but also keep dilution risk in focus. On profitability milestones, bears are being proven right for now.

With Yatsen Holding still loss making and leaning on cash of about RMB 1.06b alongside recent convertible financing, you may want to stress test the balance sheet. Check the financial health analysis of Yatsen Holding stock to see how the runway compares with the current burn and dilution risk assumptions.

Stay Ahead of Your Next Move

If Yatsen Holding's mix of strong skincare momentum and widening losses has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a cleaner entry point. Once you decide to take a position, use the Portfolio Command Center to cut through noise and focus on material updates that actually matter for your thesis. For a longer term view, tap into the Community to see how other investors are reacting to key catalysts and risk signals. By spotting both emerging opportunities and pressure points early, you give yourself a better chance of staying ahead of the market.

Seeking Alternatives Beyond Yatsen Holding

Fresh ideas can move quickly. Stocks breaking into new momentum or quietly dropping into value zones often get caught before most investors notice. Scan these curated ideas while it matters and get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.